Illumina Inc. ($ILMN) Stock Forecast: Up 5.4% Today

What is Illumina Inc.?

Illumina Inc. (ILMN) is a leading company in genomics, providing tools and services for genetic research and clinical applications.

Why is Illumina Inc. going up?

ILMN stock is up 5.4% on Feb 20, 2025 14:47

• ILMN stock experienced a bullish movement likely due to being highlighted alongside other healthcare stocks leveraging AI advancements for innovation.
• The mention of ILMN in discussions about companies driving advancements in genomics and clinical research could have sparked investor interest and confidence in the company's future prospects.
• The positive sentiment surrounding AI advancements in healthcare, coupled with ILMN's position in the genomics industry, likely contributed to the strong bullish movement in the stock today.

ILMN Price Chart

ILMN Technical Analysis

ILMN News

NVIDIA's Rise Puts These 3 Healthcare Stocks in the Spotlight

ILMN, IQV and DXCM are leveraging AI advancements to drive innovation in genomics, clinical research and diabetes management.

https://www.zacks.com/stock/news/2417544/nvidias-rise-puts-these-3-healthcare-stocks-in-the-spotlight

Trending Today

Maker ($MKR) Crypto Forecast: Up 5.1% Today

Sonic (prev. FTM) ($S) Crypto Forecast: Up 5.1% Today

Golem ($GLM) Crypto Forecast: Up 31.6% Today

Optimism ($OP) Crypto Forecast: Up 5.6% Today

MANTRA ($OM) Crypto Forecast: Up 10.9% Today

NEAR Protocol ($NEAR) Crypto Forecast: Down 5.1% Today

Memecoin ($MEME) Crypto Forecast: Up 5.7% Today

Ethereum ($ETH) Crypto Forecast: Up 5.1% Today

Pepe ($PEPE) Crypto Forecast: Up 5.0% Today

Ethena ($ENA) Crypto Forecast: Down 6.0% Today

Illumina Inc. Price History

23.00.2025 - ILMN Stock was down 5.5%

• Today, Illumina (ILMN) faced significant downward movement in the market, potentially due to the following factors:
• Positive earnings history and potential for surpassing estimates may have been overshadowed by shifting market sentiment linked to broader economic concerns or sector rotation.
• Cathie Wood's Ark Invest making notable trades involving various stocks while not increasing their investment in Illumina could have indicated waning confidence in the company.
• Investor response might be connected to uncertainties regarding Illumina's future growth opportunities or competitive pressures within the genomics sector.
• The bearish trend in Illumina's stock price today could have been influenced by overall market conditions and macroeconomic factors.

04.01.2025 - ILMN Stock was down 5.3%

• The decline in Illumina's stock today may be linked to China's decision to include ILMN in its 'Unreliable Entities List' amidst the current trade dispute with the US. This action introduces uncertainty and possible disruptions to Illumina's market activities.
• Initially, the market showed positive momentum in anticipation of Illumina's upcoming earnings report, which is expected to demonstrate growth. However, the impact of China's listing overshadowed this outlook, leading to the stock's decline.
• The market's response highlights investor concerns regarding the consequences of being on China's list and the broader effects of US-China trade tensions on Illumina's business operations and financial outcomes.

13.00.2025 - ILMN Stock was up 5.1%

• Significant trades in Illumina Inc. (ILMN) by a prominent investment firm could have boosted investor confidence in the stock, leading to a bullish movement.
• Advancements in Illumina's NovaSeq X Series, including software upgrades and new kits, likely generated positive sentiment among investors, contributing to the stock's gains.
• Illumina's strong historical performance, outperforming the market over the past 20 years, may have attracted more investors to the stock, driving up its price further.
• Overall, the combination of positive news catalysts and investor interest in Illumina's innovative genomics technologies likely fueled the bullish movement in ILMN stock today.

22.10.2024 - ILMN Stock was up 5.2%

• Today, Illumina's stock saw an upturn following the announcement of the expansion of its TruSight Oncology portfolio with the release of the TSO 500 v2 assay.
• The market responded favorably to this news, anticipating that the new assay will improve comprehensive genomic profiling (CGP) of tumors, demonstrating Illumina's dedication to advancing cancer research and treatment.
• Investors perceive this expansion as a strategic decision that may drive future revenue growth for Illumina, fostering increased confidence and stock purchases.

14.00.2025 - ILMN Stock was down 5.1%

• The company raised its Q4 revenue guidance to $1.10 billion, surpassing expectations, and anticipated strong margins. However, the stock faced downward pressure.
• Notable transactions involving Illumina by Cathie Wood's Ark Invest could have impacted market sentiment.
• Developments within Illumina's NovaSeq X Series, such as software enhancements and new kits, may drive future growth positively, but market reactions might have been influenced by other factors.

04.01.2025 - ILMN Stock was down 5.6%

• Illumina stock experienced a significant bearish movement recently.
• The decision to include Illumina in China's unreliable entities list, amidst trade war disruptions, likely influenced the stock's downward trend.
• Concerns regarding potential sanctions from the Chinese government following this listing may have unsettled investors, contributing to the bearish movement.
• Despite these challenges, analysts remain positive about Illumina's potential for earnings growth, offering a hopeful outlook for the stock's future.

09.11.2024 - ILMN Stock was up 4.5%

• The strong bullish movement in ILMN today could be attributed to positive market sentiment and potential investor optimism.
• A 9.3% decline since the last earnings report may have sparked interest among investors looking for a potential rebound opportunity.
• Investors might be speculating on positive future earnings estimates or expecting new developments in Illumina's technology and product offerings.
• Overall, the bullish movement in ILMN today could be a result of renewed confidence in the company's growth prospects and potential for a rebound from previous setbacks.

18.11.2024 - ILMN Stock was down 5.2%

• Removal from the Nasdaq-100 Index created a bearish sentiment, indicating a loss of exposure and institutional interest.
• Lackluster performance in comparison to iShares Core S&P Mid-Cap ETF (IJH) potentially raised investor unease and led to selling.
• Being taken out of the index may have caused index-based funds and institutional investors to adjust their holdings, resulting in higher sell-offs and pushing the stock price down.

16.00.2025 - ILMN Stock was down 5.4%

• Despite partnering with NVIDIA for genomic advancements and raising its Q4 revenue outlook, Illumina's stock experienced a bearish movement.
• The market may have reacted negatively due to concerns about the company's full-year revenue projection being down 2% YoY, despite exceeding street expectations for Q4 revenue.
• Additionally, Cathie Wood's Ark Invest loading up on Intellia Therapeutics and making significant trades in other companies, including Illumina, might have influenced market sentiment towards Illumina's stock negatively.
• Investors could be interpreting the layoffs at Intellia Therapeutics, one of the companies Ark Invest invested in, as a sign of potential challenges in the genomics sector, leading to a bearish movement in Illumina's stock.

07.01.2025 - ILMN Stock was down 10.3%

• Illumina (ILMN) fell short of Q4 earnings expectations, impacting investor sentiment negatively.
• Concerns emerged over the company's placement on China's unreliable entities list and the potential impact on its operations.
• Recent geopolitical tensions and earnings missing estimates have played a role in the stock's downturn despite its historical market outperformance.
• The broader market volatility and global trade relations uncertainties have potentially intensified the selling pressure on Illumina shares.

07.01.2025 - ILMN Stock was down 9.1%

• Illumina's Q4 earnings fell short of estimates, causing a decrease in the stock price and raising concerns among investors about the company's performance.
• The company's inclusion on China's unreliable entities list added more pressure on the stock, creating uncertainties about its future operations and growth in a significant market.
• Despite the recent decline, Illumina's strong historical market performance over the past two decades highlights its track record and potential for long-term growth, making it an appealing option for investors seeking stability in the genomics sector.

20.01.2025 - ILMN Stock was up 5.4%

• ILMN stock experienced a bullish movement likely due to being highlighted alongside other healthcare stocks leveraging AI advancements for innovation.
• The mention of ILMN in discussions about companies driving advancements in genomics and clinical research could have sparked investor interest and confidence in the company's future prospects.
• The positive sentiment surrounding AI advancements in healthcare, coupled with ILMN's position in the genomics industry, likely contributed to the strong bullish movement in the stock today.